PMID- 28256086
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20180821
IS  - 2059-2310 (Electronic)
IS  - 2059-2302 (Linking)
VI  - 89
IP  - 5
DP  - 2017 May
TI  - Males without apparent alloimmunization could have HLA antibodies that recognize 
      target HLA specificities expressed on cells.
PG  - 285-292
LID - 10.1111/tan.13000 [doi]
AB  - BACKGROUND AND OBJECTIVES: Human leukocyte antigen (HLA) antibodies, which are 
      involved in the development of transfusion-related side effects such as 
      transfusion-related lung injury, are sometimes found in males without a history 
      of alloimmunization (eg, transplantation and transfusion). Whether HLA antibodies 
      in male donors can interact with their target HLA specificities expressed on 
      cells have not been completely investigated. MATERIALS AND METHODS: The HLA 
      antibodies detected in 7 male donors were characterized. Flow cytometry and 
      immunocomplex capture fluorescence analysis were performed to evaluate the 
      ability of these antibodies to bind with target HLA specificities expressed on 
      cells. The association of these antibodies with complement was examined using 
      anti-C1q antibody. Sustainability of HLA antibodies over time was compared in 26 
      male vs 57 female donors. RESULTS: The antibodies from all 7 donors recognized 
      intact HLA molecules coated onto microbeads. The antibodies in 2 of 7 donors also 
      recognized their target HLA specificities expressed on cells. Furthermore, the 
      antibodies in one of these 2 donors showed HLA specificities that involved 
      complement binding. Twenty-one of 26 initially positive male donors had turned 
      negative for HLA antibody at least 1 year after their initial positive screening, 
      whereas HLA antibody positivity was maintained for a long time in most female 
      donors. CONCLUSION: Males without apparent alloimmunization could have HLA 
      antibodies that recognize their target HLA specificities on cells and that could 
      potentially modify molecular events in affected cells.
CI  - (c) 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Nakamura, J
AU  - Nakamura J
AD  - Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan.
FAU - Nakajima, F
AU  - Nakajima F
AD  - Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan.
FAU - Kamada, H
AU  - Kamada H
AD  - Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan.
FAU - Tadokoro, K
AU  - Tadokoro K
AD  - Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
FAU - Nagai, T
AU  - Nagai T
AUID- ORCID: 0000-0003-4559-671X
AD  - Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan.
FAU - Satake, M
AU  - Satake M
AD  - Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170302
PL  - England
TA  - HLA
JT  - HLA
JID - 101675570
RN  - 0 (Antigen-Antibody Complex)
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
RN  - 9007-36-7 (Complement System Proteins)
SB  - IM
MH  - Adult
MH  - Antibody Specificity
MH  - Antigen-Antibody Complex/*blood
MH  - *Blood Donors
MH  - Complement System Proteins/*metabolism
MH  - Female
MH  - Flow Cytometry
MH  - HLA Antigens/*blood
MH  - Humans
MH  - Isoantibodies/*blood
MH  - Male
MH  - Protein Binding
MH  - Sex Factors
MH  - Transfusion-Related Acute Lung Injury/prevention & control
OTO - NOTNLM
OT  - HLA
OT  - HLA antibody
OT  - TRALI
OT  - blood donors
EDAT- 2017/03/04 06:00
MHDA- 2018/06/12 06:00
CRDT- 2017/03/04 06:00
PHST- 2016/08/15 00:00 [received]
PHST- 2017/01/18 00:00 [revised]
PHST- 2017/02/10 00:00 [accepted]
PHST- 2017/03/04 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
PHST- 2017/03/04 06:00 [entrez]
AID - 10.1111/tan.13000 [doi]
PST - ppublish
SO  - HLA. 2017 May;89(5):285-292. doi: 10.1111/tan.13000. Epub 2017 Mar 2.